Sherene Loi, MD
@LoiSher
Followers
4K
Following
3K
Media
69
Statuses
920
Professor, Medical Oncologist, #LoiLab @PeterMacCC @UniMelb @NBCFAus Endowed Chair, #IBSCG cochair @etop_ibcsg, @TILsWorkgroup cofounder; own views
Melbourne, Australia
Joined August 2011
Our latest review is out now on targeting #BreastCancer #Immunity #tme #trm #CancerResearch many thanks to @NatureRevCancer
@PeterMacCC @PeterMacRes @TILsWorkGroup
Towards targeting the breast cancer immune microenvironment
1
11
46
Congratulations to @MyriamChalabi !!
Wow! Not 1️⃣, not 2️⃣, but 3️⃣‼️@Nature papers concomitantly published during #ESMO25 @myESMO
@LoiSher @adam_grippin @MDAndersonNews @PeterMacCC @NKI_nl @DrChoueiri @VanAllenLab @FAndreMD congrats to all authors and 🙏 for making this very unique session happen also @Nature ! 👇
0
1
11
♨️hot off the press2: following after my abstract @myESMO #ESMO25 in the basic science outstanding oral abstract session was @adam_grippin also published now in @Nature . 👏 Qu: Should we now be thinking about recommending a covid vaccine to all our #TNBC patients just prior to
🤯 New in @Nature from @MDAndersonNews colleagues @adam_grippin @StevenLin_MDPhD SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade https://t.co/kiZCCnf5Uw
2
3
26
📌 Just a shout-out that the Peter Mac Breast Cancer Education day is on again NEXT WEEK. @PeterMacCC THURSDAY 30th OCTOBER 10-5.30pm with networking drinks after. With special guest Prof. @hoperugo from City of Hope CA. WITH #ESMO25 just behind us this will provide
0
2
15
👏👏Bravo @LMalorni @etop_ibcsg This important study shows that endocrine therapy and CDK4+ HER2 targeting therapy in HR+ HER2+ is highly effective with similar rates of pCR to taxol+TP! Supports #Patina study & also removing #chemotherapy in the early stage HER2+ HR+ setting.
🆕 article in press: primary results from the randomized phase II TOUCH trial of neoadjuvant palbociclib + letrozole vs paclitaxel combo with trastuzumab + pertuzumab in pts with HR+/HER2+ EBC @LMalorni
https://t.co/euPGLKqwUD
0
10
45
👏This was a colloboration with @LMackayLab @TheDohertyInst Terry Speed; Jane Visvader @WEHI_research @malaysia Dr Jia Wern Pan @reversecancer & the Darcy and Neeson labs @PeterMacRes with @pssavas @BalajiVirassamy 👏👏
0
0
5
Pregnancy and breastfeeding induces the accumulation of specialized immune cells that reduce the chances of breast cancer developing https://t.co/rVId8ISQRe
nature.com
Nature - The protective, long-lived T cells can persist for decades after a woman gives birth.
3
30
126
Why does breastfeeding lower breast cancer risk? A new Nature study led by Prof @LoiSher shows it creates long-lived CD8⁺ T cells in breast tissue – immune “guards” that help stop cancers forming, including triple-negative. 🔗 https://t.co/yPMQJwiN61
0
2
14
Parity and breastfeeding reduce the risk of breast cancer via accumulation of resident memory CD8 T cells in breast tissue @Nature @LoiSher @LMackayLab
@PeterMacCC @UniMelb @BalajiVirassamy @pssavas
https://t.co/EeOabttNsr 🇦🇺
0
16
71
✨✨hot off the press from the #loilab. We show here that pregnancy & breastfeeding is associated with increased T cells in the normal breast and protection against #tnbc #breastcancer moving the role of immunity from treatment to prevention. 👏👏Thanks to @FAndreMD @DrChoueiri
Translational data shows that #breastfeeding helps personal immunity improving CD8+ T This work can help to understand better the immune system and breastfeeding mechanisms @LoiSher @OncoAlert #ESMO25 @FernandoOnco
5
34
91
😳 no OFS with endocrine therapy for premenopausal #breastcancer patients would be a great advance #esmo25 #esmoambassadors
#bcsm
Very interesting preliminary data to support the use of oral #SERD (in this case #giredestrant) without ovarian function suppression in premenopausal women with HR+/HER2- early #BreastCancer
@OncoAlert @myESMO #ESMO25 @AnnPartridgeMD
6
13
52
KEYNOTE-905 #ESMO25 Presidential #GU #MIBC - very different population to #BreastCancer! but will more MIBC patients now become Cis-ineligible? Interesting to me as a #breastcancer doc that MIBC patients accept to be randomized to EVP vs no treatment? #ESMOambassadors @OncoAlert
Bladder cancer #ESMO25 in 1 slide. #goosebumps #newSOCnow #micdrop #standingovation Neoadjuvant EVP = New SOC MIBC Cis-ineligible!
2
7
20
DB05 #esmo25 impressive efficacy for post op node + or inoperable at baseline -balanced with ~10%ILD but 👏less CNS 🧠recurrences 🙌 Bravo to those >70% patients putting up with all that nausea!! @myESMO #esmoambassadors @OncoAlert
6
11
37
a new #HER ADC "T-Bot (?)" which is better than TDM1. Agree that ocular tox 👁️ here is problem. If efficacy is equal what will patients chose? Ocular tox 👓 vs ILD 🫁vs thrombocytopenia🩸 ❓🤔 #ESMO25 #ESMOAmbassadors
#trastuzumab botidotin (HER-2 ADC w/ microtubule MMAF payload) No prior TDXd 🤷🏼♀️ Prior tras and a taxane mandated ~ 45% pertuz, ~60% prior TKI PFS 11.1 mo w/ H-botidotin vs. 4.4 mo w/ T-DM1 OS close, not quite there #ESMO25 #ESMOAmbassadors
0
2
6
#ESMO25 ?TDxD challenger? Bispecific HER2 anbenitamab shows promise in trastuzumab resistant #gastriccancer. ✅No ILD... Small study. 🇨🇳 only. Need larger international trials but this is encouraging... #ESMOAmbassadors
2
13
60
#giredestrant positive read out in #evERA. nice to see an all oral and effective combination for all HR+ patients, even though driven by ESR1mt which was nearly 50% of ITT in this largely 1L CDK4 "sensitive" population #ESMO25 #esmoambassadors @OncoAlert
Important data presented at #ESMO25 by super @elmayermd from @DFCI_BreastOnc showing the benefit of combining #giredestrant with #everolimus in patients with advanced HR+/HER2- #BreastCancer progressing on CDK4/6i #ESMO25 @OncoAlert #evERA @myESMO
1
10
23
Bravo @etop_ibcsg 👏👏 #positive @fredrophd Those who had a child even did numerically better than the control #esmo25 #esmoambassadors #bcsm
“We made it!” @fedrophd presenting the updated results of POSITIVE. After 71 months of median follow-up, temporary interruption of ET for pregnancy was not associated with worse BC outcomes. Super news for patients! 👏 groups & investigators for this academic effort. #ESMO25
0
7
18